ESTRELLA IMMUNOPHARMA, INC. (ESLAW) Operating income 2021–2025
ESTRELLA IMMUNOPHARMA, INC. (ESLAW) annual operating income history from SEC filings — each fiscal year as reported.
-$13.1MFY2025 · since FY2021: -$249,146 → -$13.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$13.1M | — |
| FY2023 | -$7.3M | +34.2% |
| FY2022 | -$11.1M | -4361.0% |
| FY2021 | -$249,146 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ESLAW financial trends
ESLAW RevenueESLAW Net incomeESLAW Net marginESLAW Gross profitESLAW Gross marginESLAW Operating marginESLAW Operating cash flowESLAW Free cash flowESLAW Capital expendituresESLAW Return on equityESLAW Stock buybacksESLAW Dividends paidESLAW Total assetsESLAW Total liabilitiesESLAW Shareholders’ equityESLAW overview →